BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
Home
»
Newsletters
» BioWorld
BioWorld
June 13, 2007
View Archived Issues
Par Pharmaceutical Gains Rights To Phase III Drug From Immtech
Par Pharmaceutical Cos. Inc. gained exclusive rights in the U.S. to a Phase III drug from Immtech Pharmaceuticals Inc. for treating pneumocystis pneumonia in AIDS patients. (BioWorld Today)
Read More
Coley Acquires TLR7 And TLR8 Programs From 3M For $20M
Read More
Xanthus Gets SPA Clearance For Trials In Secondary AML
Read More
NewCo News: Aquinox Targets SHIP Enzyme, Sets Sail With $14.5M Series A
Read More
Roxro Adds $42M Privately To Support Pain Drug Development
Read More
Other News To Note
Read More
Clinic Roundup
Read More